These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12759288)

  • 1. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
    Padyukov L; Lampa J; Heimbürger M; Ernestam S; Cederholm T; Lundkvist I; Andersson P; Hermansson Y; Harju A; Klareskog L; Bratt J
    Ann Rheum Dis; 2003 Jun; 62(6):526-9. PubMed ID: 12759288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
    Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
    Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
    Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept].
    Stojanović S; Jevtović-Stoimenov T; Stanković A; Pavlović D; Neković J; Stamenković B; Dimić A; Marinković M
    Srp Arh Celok Lek; 2011; 139(11-12):784-9. PubMed ID: 22338476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.
    Schotte H; Schlüter B; Drynda S; Willeke P; Tidow N; Assmann G; Domschke W; Kekow J; Gaubitz M
    Ann Rheum Dis; 2005 Apr; 64(4):575-81. PubMed ID: 15345504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.
    Jančić I; Arsenović-Ranin N; Sefik-Bukilica M; Zivojinović S; Damjanov N; Spasovski V; Srzentić S; Stanković B; Pavlović S
    Rheumatol Int; 2013 Jun; 33(6):1481-6. PubMed ID: 23233117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
    Klareskog L; van der Heijde D; de Jager JP; Gough A; Kalden J; Malaise M; Martín Mola E; Pavelka K; Sany J; Settas L; Wajdula J; Pedersen R; Fatenejad S; Sanda M;
    Lancet; 2004 Feb; 363(9410):675-81. PubMed ID: 15001324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.